Autonomix Medical, Inc. (AMIX) Price & Analysis

Q: What was Autonomix Medical, Inc.’s price range in the past 12 months?

Autonomix Medical, Inc. lowest stock price was $0.60 and its highest was $4.58 in the past 12 months.

Q: What is Autonomix Medical, Inc.’s market cap?

Autonomix Medical, Inc.’s market cap is $4.17M.

Q: When is Autonomix Medical, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Autonomix Medical, Inc. overvalued?

According to Wall Street analysts Autonomix Medical, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Autonomix Medical, Inc. pay dividends?

Autonomix Medical, Inc. does not currently pay dividends.

Q: What is Autonomix Medical, Inc.’s EPS estimate?

Autonomix Medical, Inc.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Autonomix Medical, Inc. have?

Autonomix Medical, Inc. has 6,907,678 shares outstanding.

Q: Which hedge fund is a major shareholder of Autonomix Medical, Inc.?

Currently, no hedge funds are holding shares in AMIX

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

150 Followers

AMIX Stock Chart & Stats

$0.63

-$0.14(-4.75%)

At close: Jan 08 4:00 PM EST

$0.63

-$0.14(-4.75%)

Day’s Range― - ―

52-Week Range$0.60 - $4.58

Previous CloseN/A

Volume72.00K

Average Volume (3M)456.51K

Market Cap

$4.17M

Enterprise Value$9.57M

Total Cash (Recent Filing)$7.48M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.09

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-12.53

Shares Outstanding6,907,678

10 Day Avg. Volume742,337

30 Day Avg. Volume456,513

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.38

Price to Sales (P/S)0.00

P/FCF Ratio-0.37

Enterprise Value/Market Cap2.30

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-180.51

Enterprise Value/Ebitda-0.58

Forecast

1Y Price Target

$5.00

Price Target Upside693.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical SuccessAMIX announced positive preliminary results from the first 15 patients of its proof-of-concept trial, showing significant and sustained pain reduction.

Market OpportunityThe potential to expand the addressable market beyond pancreatic cancer pain to other visceral cancers and earlier-stage pancreatic cancers could significantly enhance market opportunities.

Regulatory ProgressAMIX is on track regarding the regulatory timeline for its microchip-based platform technology, with a combined sensing and ablation early feasibility study expected to begin followed by a US pivotal trial.

Bears Say

Revenue ConcernsAMIX did not recognize any revenue during the quarter, and no revenue recognition is forecasted for the current or the next fiscal year.

Autonomix Medical, Inc. News

Autonomix files to sell 13.5M shares of common stock for holders

This offering relates to the resale by the selling stockholder of up to an aggregate of 9,003,332 shares...

23d ago

AMIX

Autonomix Medical Raises $5M in Private Placement

Autonomix Medical, Inc. ( ($AMIX) ) just unveiled an announcement. On November 18, 2025, Autonomix Medical, Inc. entered...

30d ago

AMIX

Autonomix prices 4.5M shares at $1.11 in private placement

Autonomix (AMIX) Medical entered into a securities purchase agreement with a single institutional investor to purchase 4,501,666 shares...

1M ago

AMIX

Autonomix reports results from exploratory subgroup analysis on PoC study

Autonomix (AMIX) Medical announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study,...

1M ago

AMIX

Promising Future for Autonomix Medical, Inc.: Buy Rating Backed by Clinical Progress and Strong Financials

Analyst Anthony Vendetti of Maxim Group reiterated a Buy rating on Autonomix Medical, Inc., retaining the price target...

1M ago

AMIX

Autonomix Medical Holds Annual Stockholders Meeting

The latest announcement is out from Autonomix Medical, Inc. ( ($AMIX) ). On October 30, 2025, Autonomix Medical,...

2M ago

AMIX

Autonomix granted U.S patent on platform enabling precision therapies

Autonomix (AMIX) Medical announced the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,369,852,...

2M ago

AMIX

Autonomix launches GLP study for Sensing and RF ablation system

Autonomix (AMIX) “announced that it has commenced a Good Laboratory Practice (GLP) preclinical study required by the FDA...

3M ago

AMIX

Autonomix files to sell 2.5M shares of common stock for holders

17:15 EDT Autonomix (AMIX) files to sell 2.5M shares of common stock for holders Published first on TheFly...

3M ago

AMIX

Autonomix announces longer-term post hoc data from PoC 1 trial

Autonomix (AMIX) Medical announced new longer-term post hoc data from its initial trial phase of its first-in-human study...

4M ago

AMIX

Autonomix Medical Raises Stock Sales Price

The latest announcement is out from Autonomix Medical, Inc. ( ($AMIX) ). Autonomix Medical, Inc. announced an increase...

4M ago

AMIX

Autonomix Medical Enters $15M Purchase Agreement

An update from Autonomix Medical, Inc. ( ($AMIX) ) is now available. On August 25, 2025, Autonomix Medical,...

4M ago

AMIX

Autonomix files to sell 1.57M shares of common stock for holders

17:04 EDT Autonomix (AMIX) files to sell 1.57M shares of common stock for holders Published first on TheFly...

4M ago

AMIX

Autonomix granted new European patent for catheter-based technology

Autonomix (AMIX) Medical announced that European Patent Office, EPO, has granted Patent No. 3,697,298, titled, “Medical Device with...

4M ago

AMIX

AMIX FAQ

What was Autonomix Medical, Inc.’s price range in the past 12 months?

Autonomix Medical, Inc. lowest stock price was $0.60 and its highest was $4.58 in the past 12 months.

What is Autonomix Medical, Inc.’s market cap?

Autonomix Medical, Inc.’s market cap is $4.17M.

When is Autonomix Medical, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Autonomix Medical, Inc.’s earnings last quarter?

Currently, no data Available

Is Autonomix Medical, Inc. overvalued?

According to Wall Street analysts Autonomix Medical, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Autonomix Medical, Inc. pay dividends?

Autonomix Medical, Inc. does not currently pay dividends.

What is Autonomix Medical, Inc.’s EPS estimate?

Autonomix Medical, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Autonomix Medical, Inc. have?

Autonomix Medical, Inc. has 6,907,678 shares outstanding.

What happened to Autonomix Medical, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Autonomix Medical, Inc.?

Currently, no hedge funds are holding shares in AMIX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Autonomix Medical, Inc.

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

AMIX Stock 12 Month Forecast

Average Price Target

$5.00

▲(693.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.3353846153846154,1.6407692307692308,1.9461538461538461,2.2515384615384617,2.556923076923077,2.8623076923076924,3.167692307692308,3.473076923076923,3.7784615384615385,4.083846153846154,4.389230769230769,4.694615384615385,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.3353846153846154,1.6407692307692308,1.9461538461538461,2.2515384615384617,2.556923076923077,2.8623076923076924,3.167692307692308,3.473076923076923,3.7784615384615385,4.083846153846154,4.389230769230769,4.694615384615385,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.3353846153846154,1.6407692307692308,1.9461538461538461,2.2515384615384617,2.556923076923077,2.8623076923076924,3.167692307692308,3.473076923076923,3.7784615384615385,4.083846153846154,4.389230769230769,4.694615384615385,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.599,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.4,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.706,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.92,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.48,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.76,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.76,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >